Litigation
Under Armour Loses Traction and Puts Chart Support Into Question
Shares of the shoe and apparel maker are reacting to reduced revenue guidance and word of government investigations into its accounting practices.
Is the Worst Over for Johnson & Johnson?
A lot of investing is just waiting until the market hates good companies.
A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks
Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.
These Drug Cos. Could Soon Feel Big Side Effects of Opioid Crisis
No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.
Johnson & Johnson Rises on $572 Million Fine That's Smaller Than Feared
Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.
Johnson & Johnson Is in the News, but How Do the Charts Look?
I am not focused on today's price movement of the stock but the pattern from the end of 2017.
Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon
Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.
Why Wall Street Is Still Riding With Uber
Uber's crash on earnings does not mean the stock is totaled according to analysts covering the stock.
NL Industries Enjoys Big Day in the Sun After Lawsuit Cloud Lifts
Announcement of a settlement of a lead paint legal tussle that had gone on for nearly two decades gave NL shares a boost Thursday.
CannTrust Is Caught in a Cannabis Catch-22
The loss of clients is a primary concern here.